Licarin A as a Novel Drug for Inflammatory Eye Diseases
Mayara Rodrigues Brandão de Paiva1, Daniel Vítor de Vasconcelos-Santos2, Márcio Matos Coelho1
1Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Abstract:
This study investigated the safety and therapeutic efficacy of licarin A (LCA) in the treatment of intraocular inflammation. In vitro safety of LCA in retinal pigmented epithelial cells (ARPE-19) and human embryonic stem cell derived-retinal pigmented epithelial cells (hES-RPE) was evaluated using CellTiter-Blue® kit. The chorioallantoic membrane (CAM) assay was used to investigate LCA safety and antiangiogenic activity. In vivo safety of intravitreal LCA was accomplished by clinical examination (including assessment of intraocular pressure), electroretinography (ERG), and histopathology. Uveitis was induced in rats by subcutaneous and intravitreal injection of bacillus Calmette-Guérin (BCG) antigen of Mycobacterium bovis. Intraocular inflammation was graded by slit-lamp and fundus examination, ERG, and histopathology. LCA was safe to cells and to the CAM at concentration below 12.0 μM. LCA significantly reduced the percentage of blood vessels in the CAM. Retinal safety and anti-inflammatory efficacy of intravitreal injection of LCA 6.0 μM were confirmed through clinical, functional, and histopathological evaluation. Significant reduction of inflammatory cytokines (tumor necrosis factor-α and interleukin-6) was also found, when compared to untreated animals. The results suggest that LCA is a potential new drug for the treatment of inflammatory eye disease.
More Related Videos
09:20Novel Photoacoustic Microscopy and Optical Coherence Tomography Dual-modality Chorioretinal Imaging in Living Rabbit Eyes
Published on: February 8, 2018
06:19Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Angle Closure Glaucoma: Treatment
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Cholinergic Antagonists: Pharmacokinetics
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
